Expanding access to newer agents-such as menin inhibitors (targeting epigenetic dysregulation), FLT3 inhibitors (addressing FLT3-mutated AML), and IDH1/2 inhibitors (used in AML with isocitrate dehydrogenase mutations)-and outpatient-based therapy protocols could also improve adherence and tolerance in frail populations. The gene discussed is MEN1; the disease is acute myeloid leukemia.